Welcome to the Value Driven Pharma Event

What happened since last year’s Value Driven Pharma event? Health Care Reform, that’s what. So, now what?

The American Recovery and Reinvestment Act (ARRA) allocated $1.1 Billion for Comparative Effectiveness Research.

Obtain the tools to deliver solid economic health data applicable to real-world needs and decisions faced by patients, clinicians and payers necessary to obtain formulary placement.

The expansions outlined in ARRA will cover approximately 19 million uninsured beginning in 2014, increasing to 30 million by 2016.

Respond to the shifting payer mix and optimize your formulary and reimbursement strategy to ensure to reap the benefits of increased prescription volumes.

ARRA sets asides $19 billion to incent the adoption of Health Information Technology by doctors and hospitals.

Register now for Value Driven Pharma to navigate the changing reimbursement paradigm to ensure your product’s value is undisputable.

In addition, to helping you develop an organizational healthcare reform response strategy to comply with new regulations while containing costs, Value Driven Pharma provides the tactical and operational tools to:

• Evaluate the appropriate use of outcomes based pricing agreements and uncover opportunities for them within your portfolio
• Explore current risk-sharing contracts like CIGNA & Merck and Health Alliance & P&G
• Develop your clinical trial dossier to demonstrate benefit and deliver expected value metrics to all stakeholders
• Establish deeper relationships with health plans and government payers
• Understand quality measures, performance guidelines and value based purchasing
• Integrate a robust value proposition earlier in product development